Effi cacy, tolerability and drug resistance of highly active anti | 818
Journal of Antivirals & Antiretrovirals

Journal of Antivirals & Antiretrovirals
Open Access

ISSN: 1948-5964

Effi cacy, tolerability and drug resistance of highly active antiretroviral therapy to patients with HIV/AIDS in China

International Conference and Exhibition on VIROLOGY

5-7 September 2011 Baltimore, USA

Wang Chongjian, Li Yuqian, Wang Yuming, Liang Shuying, Guo Jinling, Li Zizhao, Zhang Weidong and Li Wenjie

Scientific Tracks Abstracts: JAA

Abstract :

Objective: To evaluate the clinical effi cacy, tolerability and drug resistance on highly active antiretroviral therapy (HAART), and then provide scientifi c evidence for antiretroviral therapy and reducing drug resistance Methods: 266 HIV-seropositive individuals, who met the conditions of WHO recommendation antiretroviral therapy, were enrolled in a prospective study in April 2007 (regimen:AZT+DDI+NVP or AZT+DDI+EFV), and then 239 patients completed 12 months antiretroviral therapy. Clinical symptom, CD4+ T cell count and viral load were measured before and aft er HAART, and drug resistance and reason of stopping antiretroviral therapy were also monitored for HIV/AIDS patients receiving HAART. Results: Aft er HAART, the eff ective rate of fever, cough, diarrhea, lymphadenectasis, weight loss, tetter, debility and fungous infection was 92.55%, 93.13%, 93.71%, 91.18%, 91.18%, 89.00%, 92.25% and 80.65%, respectively (Table 1). CD4+T cell count aft er HAART (353.39�203.47 cells/ml) was signifi cantly increaser than before HAART (258.84�198.26 cells/ml) (P<0.05). Th e viral load aft er HAART (4061.88�1367.18 copies/ml) was signifi cantly declined than before HAART (6616.48�1569.67 copies/ml) (P<0.05) (Table 2). Th e rate of drug resistance was 7.81% (AZT), 17.19% (DDI), 37.50% (EFV) and 31.25% (NVP), respectively (Table 3). Th erapy schedule of 27 patients was stopped due to a variety of reasons, such as death, dizziness, liver damage, bellyache et al. Except for eight death cases, three suicides were discovered at 22, 35 and 56 days respectively aft er stopping therapy (Table 4). Conclusion: HAART could eff ectively improve the clinincal symptoms of HIV/AIDS patients, and increase the count of CD4+T cell and reduce the viral load and inhibit virus replication. Drug resistance may be the key factor restricting the clinical effi cacy.